|
|
Post by barnstormer on Jul 28, 2018 23:20:06 GMT -5
I guess we will see during ther earnings call. I hope I am dead arse wrong. But to ignore the sp at his point is not good investing. GLT all
|
|
|
|
Post by barnstormer on Jul 28, 2018 23:28:40 GMT -5
Lefty, I am not sure why you are such a negative person yourself and like to take personal pokes against me. I have posted many positive things about MNKD. I even go to the meetings and speak to Mike and his team myself. WTF do you do but post and criticize others that don't share your opinion?
|
|
|
|
Post by roguesuerte on Jul 28, 2018 23:29:36 GMT -5
By biggest position in my portfolio I mean largest amount I have spent my hard earned money on. I am hoping these monies are in limbo at the moment and that I will recoup my losses at some point(down about 135k at this point). I am not averaging down on MNKD at this point anymore. I think Mgmt. has made strides on many fronts, but not the important one, selling Afrezza.
I am assuming that advertising has stopped at this point, script numbers still relatively stagnant, and large debt looming.
Fortunately I am hugely diversified in other small/large cap biotechs, Reits, BDC's, oil plays,etc.. Im holding like 50 other positions many of them winners to help offset my potential losses here. I justified buying MNKD as I believed, like Kendall that Afrezza is a game-changed for PWD's. Having the best drug in class by no means assures success as I have been learning recently though positions in MNKD, SGYP, GERN, GILD. Hell of a lot of moving parts in any biotech large or small cap.
One of my positions I exited too soon was TASR or AXON. Tasers Bodycams, etc...When they announced they would provide free bodycams to police for enrolling in their cloud-based evidence recording service I was abit skeptical on how things would playout so I sold. AXON has almost tripled since then.Unless Mike and cohorts have a card up their sleeve i.e buyout/partnership with major BP I think we are in trouble here. .Maybe approach a Dexcom or Abbott and throw in a 3 mth supply of Afrezza with the cgm purchase, or something like that. We still have Danbury producing Afrezza with an exp. date but few buyers at this point.
|
|
|
|
Post by awesomo on Jul 28, 2018 23:36:57 GMT -5
Saying negative things is not undermining mnkd. I would rather see negative but fact based posts instead of the over the top "I can predict the future" posts such as "No reason to worry. Mike will find the money" and " Because of Afrezza the pump is dead". I picture satisfied Afrezza users, along with friends and relatives of such users, thinking about investing in the company behind this wonderful drug and winding up on this board -- where they would see messages of despair and warnings of impending bankruptcy. That's gotta drive away potential investors. There’s a difference between Afrezza the product and MannKind the company. If you want to invest in MannKind you should absolutely know the risk and the history. There’s no arguing the fact that investing in MannKind the company long term has been an unmitigated disaster up to this point. Nobody here is screaming bankruptcy, but lack of cash and dilution are serious concerns that will affect shareholders. Besides, if these people let a few random users on a message board dictate where they invest their money, they probably shouldn’t be investing in the first place. Also, these investors surely won’t be influencing the share price. |
|
|
|
Post by mytakeonit on Jul 29, 2018 0:19:47 GMT -5
Well I guess we will be getting a better and bigger picture at the conference call. As for me, E*Trade is finally working the transfer so I should be loading a few more shares early next week. (Fingers crossed ... and eyes crossed)
And, sports was correct ... I am rich. They call me Richie Rich ... and sometimes I am considered a cartoon character. Go figure ...
|
|
|
|
Post by sportsrancho on Jul 29, 2018 6:59:01 GMT -5
The commercials have not stopped, don’t you guys read the board? It’s under articles.
Really only two people cover Mannkind stock and that’s Nate’s Notes and Spencer. When you go to do research there’s really only 3 places to go. I think it matters, it matters a lot...but it’s your money. Also people need a place to discuss things intelligently and throw ideas back-and-forth and I’m all for that.
On the other hand I totally understand what Nylefty is saying about friends and family. Almost everywhere you go it’s negative except for Nate. Obviously we have no buyers.
Retail investors will just wait until institutional investors start to buy and then ride the runner-up:-) The sentiment is too bad otherwise.
But .....the rich get richer, that’s mytakeonit:-))
|
|
|
|
Post by hellodolly on Jul 29, 2018 7:38:09 GMT -5
"...afrezza is not a superior insulin but rather a superior approach to treating diabetes."
Sayhey, why must you always hit home runs. You do know base hits win games, too?
Best regards - HD
|
|
|
|
Post by nylefty on Jul 29, 2018 9:43:45 GMT -5
I point out that both sales and insurance coverage have improved significantly, while Barnstormer says the situation is "desperate," that a pig wearing lipstick is still a pig, and that the next earnings call will probably be a "disaster." And I'm the one who's a "negative person?"
|
|
|
|
Post by morgieporgie on Jul 29, 2018 9:47:17 GMT -5
I point out that both sales and insurance coverage have improved significantly, while Barnstormer says the situation is "desperate," that a pig wearing lipstick is still a pig, and that the next earnings call will probably be a "disaster." And I'm the one who's a "negative person?" Gotta admit, a pig with lipstick is still a pig. |
|
|
|
Post by morgieporgie on Jul 29, 2018 10:18:20 GMT -5
Could be my expectations are too high, don't really know. I will say that if this is one of the International deals that shareholders had in mind, it is somewhat disappointing. (No mention of the deal itself, details and or cash upfront)
Morgie - I can guarantee you my expectations are much higher than yours. When I saw Amazon's earnings I told my associated MNKD has the potential of beating that. Talk about expectations and being delusional but then again maybe not.
The problem with MNKD is the foundation was never laid for afrezza to be prescribed. Listen to Dr. Kendall at the Investor's conference when he says as much. At the same time every BP including our partner was doing everything they could to poison the well.
If afrezza was already the FDA standard Mike's deals would have already been closed on his terms. This deal is not the international deals but a deal which costs no money, may bring another IB into the picture and gets Mike some experience in closing deals.
MNKD is finally in the process of putting the horse before the cart. Now its going to take awhile. As it becomes the standard things will come together quickly and we will see if my expectations are met. Some people play golf for a hobby, I read scientific papers on diabetes. Call me crazy but afrezza is not a superior insulin but rather a superior approach to treating diabetes. It allows for a true paradigm shift in diabetes treatment.
Seyhey - By the way, has follow up dosing always been recommended by Mannkind? It seems they weren't pushing that from the start, which if that is indeed the case explains why people were dropping the drug so much. Would/could be why the Doctor's wouldn't precribe it much also. It simply doesn't always work correctly unless the timing is perfect using a single 4, 8, or 12 unit cartridge. The follow up dose is needed and maybe they botched the original dosage instructions. |
|
|
|
Post by mnholdem on Jul 29, 2018 10:58:21 GMT -5
I point out that both sales and insurance coverage have improved significantly, while Barnstormer says the situation is "desperate," that a pig wearing lipstick is still a pig, and that the next earnings call will probably be a "disaster." And I'm the one who's a "negative person?" IMO a smart investor always tries to assess the situation with a critical eye. The cash situation should be considered dire in the absence of news from management. It’s the same situation with sales growth. An investor who points this out should not automatically be labeled as a negative person. Facts are neither negative nor positive. CEO often paint an optimistic picture but that’s part of the job. An investor with a critical eye may notice that, even though sales have been slowly increasing since Michael was hired as Chief Commercial Officer, acceptance of Afrezza has been dismal compared to weekly prescriptions of Novolog/Humalog. Is that a negative statement? I don’t think so. It’s simply a fact. I suggest lightening up on posters who comment about risks. Risk is always present. Just read the Risks section of every 10-K filing. |
|
|
|
Post by uvula on Jul 29, 2018 11:03:03 GMT -5
And this is why mnholdem is a global moderator. I think you summed up this thread perfectly.
|
|
|
|
Post by sportsrancho on Jul 29, 2018 11:08:26 GMT -5
Morgie - I can guarantee you my expectations are much higher than yours. When I saw Amazon's earnings I told my associated MNKD has the potential of beating that. Talk about expectations and being delusional but then again maybe not.
The problem with MNKD is the foundation was never laid for afrezza to be prescribed. Listen to Dr. Kendall at the Investor's conference when he says as much. At the same time every BP including our partner was doing everything they could to poison the well.
If afrezza was already the FDA standard Mike's deals would have already been closed on his terms. This deal is not the international deals but a deal which costs no money, may bring another IB into the picture and gets Mike some experience in closing deals.
MNKD is finally in the process of putting the horse before the cart. Now its going to take awhile. As it becomes the standard things will come together quickly and we will see if my expectations are met. Some people play golf for a hobby, I read scientific papers on diabetes. Call me crazy but afrezza is not a superior insulin but rather a superior approach to treating diabetes. It allows for a true paradigm shift in diabetes treatment.
Seyhey - By the way, has follow up dosing always been recommended by Mannkind? It seems they weren't pushing that from the start, which if that is indeed the case explains why people were dropping the drug so much. Would/could be why the Doctor's wouldn't precribe it much also. It simply doesn't always work correctly unless the timing is perfect using a single 4, 8, or 12 unit cartridge. The follow up dose is needed and maybe they botched the original dosage instructions. sayhey would know, but I believe that is true, also people were not taking enough units halfway into the meal the very first time. A lot of times if you do that you do not need a second dose. Just depends... |
|
|
|
Post by morgieporgie on Jul 29, 2018 11:17:30 GMT -5
Seyhey - By the way, has follow up dosing always been recommended by Mannkind? It seems they weren't pushing that from the start, which if that is indeed the case explains why people were dropping the drug so much. Would/could be why the Doctor's wouldn't precribe it much also. It simply doesn't always work correctly unless the timing is perfect using a single 4, 8, or 12 unit cartridge. The follow up dose is needed and maybe they botched the original dosage instructions. sayhey would know, but I believe that is true, also people were not taking enough units halfway into the meal the very first time. A lot of times if you do that you do not need a second dose. Just depends... . Right, so combine not working correctly SOMETIMES, based on when taken - meal size etc.. along with a follow up dose never being even thought of or prescribed - not to mention real-world follow up dosing on mealtime insulin is a major no no due to Hypoglycemia, I can see why not many woud refill their script. |
|
|
|
Post by centralcoastinvestor on Jul 29, 2018 13:36:55 GMT -5
What does that have to do with the current MannKind management? Answer: Nothing. You're using the same outdated bashes that the shorts use on StockTwits. Correct, it has nothing to do with current management. Those words are from Al Mann himself. You are incorrect. The “Embarrassment of Riches” comment came from Matt Pfeffer and not Al Mann. |
|
